Clinical mid-term results after tricuspid valve replacement

Abstract

Tricuspid valve replacement (TVR) is associated with high mortality and morbidity. Frequently, TVR is performed in critically ill patients with high frequency of re-intervention. We analyzed our experience in TVR focusing on predicting risk factors, mid-term survival and quality of life assessed with a Short-Form 36 Health Survey (SF-36) questionnaire. Between January 1992 and May 2007, 81 consecutive patients underwent TVR (54 re-interventions, 66.7%; 46 procedures, associated with a left-sided operation, 56.8%). There were 59 females (73%) with a mean age of 59.3±11.6 years. The most prevalent etiology was rheumatic fever (61.7%). Pulmonary hypertension was present in 64%. Mean left ventricle ejection fraction (LVEF) was 56.6% and mean right ventricle ejection fraction (RVEF) was 48.1%. All but four patients (4.9%) received a bio-prosthesis. Hospital mortality was 9.88%. The mean follow-up was 61±42 months. Survival was 68% at five years. Univariate predictors of hospital mortality were atrial fibrillation (AFib) (P-0.01), associated procedures on the left heart (P<0.025) and preoperative chronic right heart failure symptoms (P<0.01). At follow-up: 10.8% of patients had a pace-maker (PM) induced rhythm; the mean SF-36 score was 51.1±4.8 (range 59-38). Age (P=0.015), associated procedures (P=0.024) and previous cardiovascular surgery (P=0.015) were univariate predictors of the SF-36 score. At a multivariate analysis LVEF, venous congestion and pulmonary artery pressures (PAPs) were related with a SF-36 score. © 2010 Published by European Association for Cardio-Thoracic Surgery. © 2010 Published by European Association for Cardio-Thoracic Surgery.